WallStreetZenWallStreetZen

NASDAQ: HSCS
Heartsciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for HSCS

Based on 1 analyst offering 12 month price targets for Heartsciences Inc

Min Forecast
$9.00+173.56%
Avg Forecast
$9.00+173.56%
Max Forecast
$9.00+173.56%

Should I buy or sell HSCS stock?

Based on 1 analyst offering ratings for Heartsciences Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HSCS stock forecasts and price targets.

HSCS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-01

1 of 1

Forecast return on equity

Is HSCS forecast to generate an efficient return?

Company
-389.48%
Industry
21.59%
Market
270.27%
HSCS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HSCS forecast to generate an efficient return on assets?

Company
-190.05%
Industry
11.44%
HSCS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HSCS earnings per share forecast

What is HSCS's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$6.47
Avg 2 year Forecast
-$4.62

HSCS revenue forecast

What is HSCS's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$1.6M+26,012%
HSCS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HSCS revenue growth forecast

How is HSCS forecast to perform vs Medical Devices companies and vs the US market?

Company
1,515.92%
Industry
7.99%
Market
58.36%
HSCS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HSCS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HSCS vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
HSCS$3.29$9.00+173.56%Buy
PTHL$0.61N/AN/A
BMRA$2.96N/AN/A
PAVM$0.41$20.00+4,801.96%Buy
INBS$1.01N/AN/A
View Top Medical Device Stocks

Heartsciences Stock Forecast FAQ

Is Heartsciences Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: HSCS) stock is to Buy HSCS stock.

Out of 1 analyst, 0 (0%) are recommending HSCS as a Strong Buy, 1 (100%) are recommending HSCS as a Buy, 0 (0%) are recommending HSCS as a Hold, 0 (0%) are recommending HSCS as a Sell, and 0 (0%) are recommending HSCS as a Strong Sell.

If you're new to stock investing, here's how to buy Heartsciences stock.

What is HSCS's earnings growth forecast for 2026-2027?

(NASDAQ: HSCS) Heartsciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 17.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 101.65%.

Heartsciences's earnings in 2025 is -$8,768,534.On average, 3 Wall Street analysts forecast HSCS's earnings for 2026 to be -$17,122,224, with the lowest HSCS earnings forecast at -$16,450,764, and the highest HSCS earnings forecast at -$17,625,819.

In 2027, HSCS is forecast to generate -$12,234,018 in earnings, with the lowest earnings forecast at -$11,754,253 and the highest earnings forecast at -$12,593,842.

What is HSCS's revenue growth forecast for 2026-2027?

(NASDAQ: HSCS) Heartsciences's forecast annual revenue growth rate of 1,515.92% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.99%, and it is also forecast to beat the US market's average forecast revenue growth rate of 58.36%.

Heartsciences's revenue in 2025 is $6,250.On average, 3 Wall Street analysts forecast HSCS's revenue for 2026 to be $0, with the lowest HSCS revenue forecast at $0, and the highest HSCS revenue forecast at $0.

In 2027, HSCS is forecast to generate $4,321,066 in revenue, with the lowest revenue forecast at $4,151,612 and the highest revenue forecast at $4,448,156.

What is HSCS's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: HSCS) forecast ROA is -190.05%, which is lower than the forecast US Medical Devices industry average of 11.44%.

What is HSCS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year HSCS price target, the average HSCS price target is $9.00, with the highest HSCS stock price forecast at $9.00 and the lowest HSCS stock price forecast at $9.00.

The Wall Street analyst predicted that Heartsciences's share price could reach $9.00 by Oct 1, 2026. The average Heartsciences stock price prediction forecasts a potential upside of 173.56% from the current HSCS share price of $3.29.

What is HSCS's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: HSCS) Heartsciences's current Earnings Per Share (EPS) is -$8.30. On average, analysts forecast that HSCS's EPS will be -$6.47 for 2026, with the lowest EPS forecast at -$6.21, and the highest EPS forecast at -$6.66. In 2027, HSCS's EPS is forecast to hit -$4.62 (min: -$4.44, max: -$4.76).

What is HSCS's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: HSCS) forecast ROE is -389.48%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.